Immunomodulatory News and Research

RSS

Sea water strengthens the body against viruses, low defences, bacteria and pathogens

Sea water therapy is a technique of cellular nutrition backed by more than 100 years of clinical use in hospitals, during which numerous studies have demonstrated its beneficial effects on patients' health.

29 Oct 2012

Investigators provide overview of role of dopamine in modulating the immune system

Dopamine is a neurotransmitter that is associated with emotions, movement, and the brain's pleasure and reward system. In the current issue of Advances in Neuroimmune Biology, investigators provide a broad overview of the direct and indirect role of dopamine in modulating the immune system and discuss how recent research has opened up new possibilities for treating diseases such as Parkinson's and Alzheimer's disease, schizophrenia, multiple sclerosis or even the autoimmune disorders.

11 Oct 2012

Recovering Treg cells in pancreatic lymph nodes may restore insulin production in type I diabetics

The key to restoring production of insulin in type I diabetic patients, previously known as juvenile diabetes, may be in recovering the population of protective cells known T regulatory cells in the lymph nodes at the "gates" of the pancreas, a new preclinical study published online October 8 in Cellular & Molecular Immunology by researchers in the Department of Bioscience Technologies at Thomas Jefferson University suggests.

10 Oct 2012

Hydroxychloroquine fails to modify HIV in patients not taking ART

The use of hydroxychloroquine does not reduce CD8 cell activation in HIV-infected patients not taking antiretroviral therapy, research shows.

30 Jul 2012

Kyprolis for multiple myeloma receives FDA approval under accelerated approval program

The U.S. Food and Drug Administration today approved Kyprolis (carfilzomib) to treat patients with multiple myeloma who have received at least two prior therapies, including treatment with Velcade (bortezomib) and an immunomodulatory therapy. A form of blood cancer that arises from plasma cells, multiple myeloma usually grows in bone marrow, the soft, spongy tissue found inside most bones.

21 Jul 2012

FDA grants accelerated approval for Kyprolis to treat multiple myeloma

Ligand Pharmaceuticals Incorporated today announced that its licensee, Onyx Pharmaceuticals, received accelerated approval from the U.S. Food and Drug Administration (FDA) for Kyprolis (carfilzomib) for Injection, a proteasome inhibitor indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

21 Jul 2012

FDA grants accelerated approval to Onyx's Kyprolis for treatment of multiple myeloma

Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Kyprolis (carfilzomib) for Injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

21 Jul 2012

Onyx receives FDA approval for Kyprolis to treat multiple myeloma

The Multiple Myeloma Research Foundation (MMRF) today announced that its partner, Onyx Pharmaceuticals, Inc., received U.S. Food and Drug Administration (FDA) approval for Kyprolis (carfilzomib) for the treatment of patients with multiple myeloma who have received at least two prior therapies, including Velcade (bortezomib) for Injection and an immunomodulatory agent, such as Thalomid (thalidomide) or Revlimid (lenalidomide), and have demonstrated disease progression on or within 60 days of completion of the last therapy.

21 Jul 2012

Studies report on therapeutic efficacy of stem cell transplantation in animal models of ALS, SCI

Two studies published in a recent issue of Cell Medicine report on the therapeutic efficacy of stem cell transplantation in animal models of amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI).

20 Jul 2012

Onyx commences ENDEAVOR Kyprolis Phase 3 trial for relapsed multiple myeloma

Onyx Pharmaceuticals, Inc. announced today that the company has begun enrollment in the ENDEAVOR trial, a Phase 3 trial evaluating Kyprolis in combination with dexamethasone, versus bortezomib with dexamethasone in patients with relapsed multiple myeloma.

2 Jul 2012

FDA ODAC votes in favor of Onyx’s Kyprolis

Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) determined by a vote of 11-0 with 1 abstention that, in patients with relapsed and refractory multiple myeloma who have received at least two prior lines of therapy that included a proteasome inhibitor and an immunomodulatory agent (IMiD), the benefit-risk assessment is favorable for the use of Kyprolis.

21 Jun 2012

Colectomy need in patients with severe ulcerative colitis drastically reduced by Kappaproct

InDex Pharmaceuticals today announced the publication of positive data from the Company's compassionate use program with its lead compound Kappaproct.

19 Jun 2012

Preliminary results from Incyte’s INCB024360 Phase I trial on solid tumors

Incyte Corporation presented preliminary results today from the ongoing Phase I clinical trial for its oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB024360, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

5 Jun 2012

EPO issues patent to Cytune’s CYP0150 for treatment of cancer

Cytune Pharma, an emerging leader in innovative immunomodulatory agents against cancer and infectious diseases, announced today that it will attend the BIO2012 to present its major achievements over the last 12 months and to foster partnering discussions.

30 May 2012

Statin therapy prevents cancer and reduces death risk in heart transplant recipients

Statins prevent cancer and reduce death from all causes in heart transplant recipients. The findings were independent of cholesterol levels.

21 May 2012

Galectin Therapeutics commences Phase 1/2 trial of new treatment combination for advanced MM

Galectin Therapeutics, the leader in developing carbohydrate-based therapeutic compounds to inhibit galectin proteins for the therapy of liver fibrosis and cancer, today announced that the first patient has been dosed in a Phase 1/2 trial evaluating the safety and efficacy of a novel treatment combination for the treatment of advanced metastatic melanoma.

16 May 2012

InDex Pharmaceuticals granted U.S. patent for novel treatment of steroid-resistant inflammation

InDex Pharmaceuticals today announced that it has been granted a patent by the United States Patent and Trademark Office. The patent provides additional protection for the use of Kappaproct® and additional DNA-based immunomodulatory sequences (DIMS) for the treatment of steroid-resistant inflammatory diseases including inflammatory bowel disease, rheumatoid arthritis, psoriasis, asthma, emphysema and chronic obstructive pulmonary disease.

26 Apr 2012

New genetic signature may predict NSCLC patients at risk of relapse

A new genetic signature identified by Spanish researchers may provide doctors with robust and objective information about which patients with early stage lung cancer are at low or high risk of relapse following surgery, investigators report at the 3rd European Lung Cancer Conference in Geneva. Their work also opens new avenues for immunotherapy for lung cancer.

19 Apr 2012

BfArM grants Moberg Derma approval to initiate Limtop clinical phase I trial for actinic keratosis

The German- Federal Institute for Drugs and Medical Devices (BfArM) has granted Moberg Derma approval to initiate a clinical phase I trial for Limtop. Limtop is an innovative formulation of an immunomodulatory compound with potential to treat actinic keratosis, genital warts and basal cell carcinoma.

11 Mar 2012

Juvenile arthritis affected kids are at a high risk of cancer: Study

A new study shows that kids with juvenile idiopathic arthritis develop cancer four times more often than children without the disease, but the treatments they receive - including biologic treatments like Enbrel - may not explain their increased risk. If confirmed, researchers say the findings should ease fears that biologic treatments known as TNF inhibitors cause cancer in children and young adults.

14 Feb 2012

Immunomodulatory News and Research

Sea water strengthens the body against viruses, low defences, bacteria and pathogens

Investigators provide overview of role of dopamine in modulating the immune system

Recovering Treg cells in pancreatic lymph nodes may restore insulin production in type I diabetics

Hydroxychloroquine fails to modify HIV in patients not taking ART

Kyprolis for multiple myeloma receives FDA approval under accelerated approval program

FDA grants accelerated approval for Kyprolis to treat multiple myeloma

FDA grants accelerated approval to Onyx's Kyprolis for treatment of multiple myeloma

Onyx receives FDA approval for Kyprolis to treat multiple myeloma

Studies report on therapeutic efficacy of stem cell transplantation in animal models of ALS, SCI

Onyx commences ENDEAVOR Kyprolis Phase 3 trial for relapsed multiple myeloma

FDA ODAC votes in favor of Onyx’s Kyprolis

Colectomy need in patients with severe ulcerative colitis drastically reduced by Kappaproct

Preliminary results from Incyte’s INCB024360 Phase I trial on solid tumors

EPO issues patent to Cytune’s CYP0150 for treatment of cancer

Statin therapy prevents cancer and reduces death risk in heart transplant recipients

Galectin Therapeutics commences Phase 1/2 trial of new treatment combination for advanced MM

InDex Pharmaceuticals granted U.S. patent for novel treatment of steroid-resistant inflammation

New genetic signature may predict NSCLC patients at risk of relapse

BfArM grants Moberg Derma approval to initiate Limtop clinical phase I trial for actinic keratosis

Juvenile arthritis affected kids are at a high risk of cancer: Study

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News